IXICO has completed a fundraising
IXICO plc, a specialist in AI-driven neuroimaging analytics, has completed a US$13.5 million gross capital raise. The funds will be used to support the company’s tech bio strategy, which will see IXICO partner its platform to maximize its potential.
IXICO is a precision neuroscience company. Its AI-enabled neuroimaging platform supports clinical trials for neurological diseases, including Alzheimer’s and Huntington’s, helping biopharma companies make better, faster decisions in drug development.
Oaklins Cavendish, one of Oaklins’ member firms in the UK, acted as the sole bookrunner and broker for IXICO plc’s US$13.5 million capital raise.
Contáctese con el equipo de la transacción
Transacciones relacionadas
UKAT Group has acquired Bayberry Limited
UK Addiction Treatment (UKAT) Group, a leading UK provider of residential addiction, mental health and behavioral health treatment backed by Sullivan Street Partners, has acquired Bayberry Limited, a specialist mental health and wellbeing treatment provider. Joining UKAT enables Bayberry to preserve continuity of care for patients and referral partners, retain the strength of its clinical team and benefit from UKAT’s operational infrastructure, referral network and marketing channels. This partnership supports Bayberry’s next stage of development while preserving the qualities that differentiate its service offering.
Conozca másMedicija has acquired Saulės Šeimos Medicinos Centras
Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.
Conozca másQuimpharma has completed the divestiture of a product portfolio to Megalabs
Quimpharma has completed the divestiture of a product portfolio to Megalabs México.
Conozca más